By supporting OCC, you are creating a future where ovarian cancer is preventable, curable, and ultimately eradicated.
OVARIAN CANCER RESEARCH IS A PRIORITY THAT WILL NOT BE IGNORED.
This research showcase serves as a comprehensive archive, highlighting pivotal studies and groundbreaking discoveries. It offers a detailed look into the vast array of research efforts aimed at understanding, diagnosing, treating, and ultimately curing ovarian cancer, documenting the progress and impact of these initiatives on the cancer community and beyond.
5
Research capacity
Advancing Research Alongside Patient Partners: Next-Generation Best Practices for Effective Collaboration in Health Research
Patient engagement best practices co-developed with OCC's Patient Partners in Research team
National
Lead Scientist: Ally Farrell and Alicia Tone (Ovarian Cancer Canada)
All types SurvivorshipClinical trial
Re-VOLVE trial: using genomics to make treatment decisions after a PARP inhibitor
Precision medicine in real time
Toronto
Lead Scientist: Dr. Stephanie Lheureux (University of Toronto)
High-grade serous TreatmentClinical trial
Tumour testing and ovarian cancer drug prediction program
Improving precision medicine options for Saskatchewan patients
Saskatoon
Lead Scientist: Dr. Laura Hopkins (University of Saskatchewan)
High-grade serous TreatmentResearch capacity
Building a scientific toolbox to study low-grade serous ovarian cancer (LGSOC)
High-quality research models of LGSOC will set the stage for discovery and testing of much-needed new treatment options
Vancouver
Lead Scientist: Dr. Mark Carey (University of British Columbia)
Low-grade serous Cancer biologyPre-clinical
Development of therapeutic vaccines against ovarian cancer
Development of therapeutic vaccines against ovarian cancer
Montreal
Lead Scientist: Dr. Claude Perreault (Université de Montréal)
All types TreatmentES2 trial: combining a PARP inhibitor and apoptosis sensitizer
- Location
- Montreal
- Lead scientist
- Dr. Diane Provencher
- Type of ovarian cancer
- High-grade serous
- Research continuum
- Clinical trial
- Ovarian cancer continuum
- Treatment
Location
Montreal
Lead scientist
Dr. Diane Provencher
Type of ovarian cancer
High-grade serous
Research continuum
Research capacity Discovery research Pre-clinical Clinical trial
Ovarian cancer continuum
Cancer biology Prevention Early detection Treatment Survivorship
Supercharging CAR-T cells for Ovarian Cancer
- Location
- Victoria
- Lead scientist
- Dr. Brad Nelson
- Type of ovarian cancer
- All types
- Research continuum
- Pre-clinical
- Ovarian cancer continuum
- Treatment
Location
Victoria
Lead scientist
Dr. Brad Nelson
Type of ovarian cancer
All types
Research continuum
Research capacity Discovery research Pre-clinical Clinical trial
Ovarian cancer continuum
Cancer biology Prevention Early detection Treatment Survivorship
Building a scientific toolbox to study low-grade serous ovarian cancer
- Location
- Vancouver
- Lead scientist
- Dr. Mark Carey
- Type of ovarian cancer
- Low-grade serous
- Research continuum
- Research capacity
- Ovarian cancer continuum
- Cancer biology
Location
Vancouver
Lead scientist
Dr. Mark Carey
Type of ovarian cancer
Low-grade serous
Research continuum
Research capacity Discovery research Pre-clinical Clinical trial
Ovarian cancer continuum
Cancer biology Prevention Early detection Treatment Survivorship
Tumour testing and ovarian cancer drug prediction program
- Location
- Saskatoon
- Lead scientist
- Dr. Laura Hopkins
- Type of ovarian cancer
- High-grade serous
- Research continuum
- Clinical trial
- Ovarian cancer continuum
- Treatment
Location
Saskatoon
Lead scientist
Dr. Laura Hopkins
Type of ovarian cancer
High-grade serous
Research continuum
Research capacity Discovery research Pre-clinical Clinical trial
Ovarian cancer continuum
Cancer biology Prevention Early detection Treatment Survivorship
Enabling precision oncology in rare types of gynecologic cancer
- Location
- Vancouver
- Lead scientist
- Dr. Mark Carey
- Type of ovarian cancer
- Low-grade serous Clear cell Mucinous
- Research continuum
- Research capacity
- Ovarian cancer continuum
- Cancer biology
Location
Vancouver
Lead scientist
Dr. Mark Carey
Type of ovarian cancer
Low-grade serous Clear cell Mucinous
Research continuum
Research capacity Discovery research Pre-clinical Clinical trial
Ovarian cancer continuum
Cancer biology Prevention Early detection Treatment Survivorship
Every Woman Study: Canadian Edition
- Location
- Toronto [pan-Canadian]
- Lead scientist
- Ovarian Cancer Canada
- Type of ovarian cancer
- All types
- Research continuum
- Discovery research
- Ovarian cancer continuum
- Treatment Survivorship
Location
Toronto [pan-Canadian]
Lead scientist
Ovarian Cancer Canada
Type of ovarian cancer
All types
Research continuum
Research capacity Discovery research Pre-clinical Clinical trial
Ovarian cancer continuum
Cancer biology Prevention Early detection Treatment Survivorship
Phase II clinical trial of CX5461 at the time of disease progression on a PARP inhibitor
- Location
- Toronto
- Lead scientist
- Dr. Amit Oza
- Type of ovarian cancer
- High-grade serous
- Research continuum
- Clinical trial
- Ovarian cancer continuum
- Treatment
Location
Toronto
Lead scientist
Dr. Amit Oza
Type of ovarian cancer
High-grade serous
Research continuum
Research capacity Discovery research Pre-clinical Clinical trial
Ovarian cancer continuum
Cancer biology Prevention Early detection Treatment Survivorship
Exploring and exploiting aberrant RBX1 expression in high-grade serous ovarian cancer
- Location
- Winnipeg
- Lead scientist
- Dr. Kirk McManus
- Type of ovarian cancer
- High-grade serous
- Research continuum
- Pre-clinical
- Ovarian cancer continuum
- Cancer biology
Location
Winnipeg
Lead scientist
Dr. Kirk McManus
Type of ovarian cancer
High-grade serous
Research continuum
Research capacity Discovery research Pre-clinical Clinical trial
Ovarian cancer continuum
Cancer biology Prevention Early detection Treatment Survivorship
Preventing ovarian cancer through the expansion of opportunistic salpingectomy
- Location
- Vancouver
- Lead scientist
- Dr. Lesa Dawson
- Type of ovarian cancer
- High-grade serous Endometrioid Clear cell
- Research continuum
- Discovery research
- Ovarian cancer continuum
- Prevention
Location
Vancouver
Lead scientist
Dr. Lesa Dawson
Type of ovarian cancer
High-grade serous Endometrioid Clear cell
Research continuum
Research capacity Discovery research Pre-clinical Clinical trial
Ovarian cancer continuum
Cancer biology Prevention Early detection Treatment Survivorship
Understanding the experience of previvors receiving care at a specialized centre
- Location
- Vancouver
- Lead scientist
- Dr. Lesa Dawson
- Type of ovarian cancer
- High-grade serous
- Research continuum
- Discovery research
- Ovarian cancer continuum
- Prevention
Location
Vancouver
Lead scientist
Dr. Lesa Dawson
Type of ovarian cancer
High-grade serous
Research continuum
Research capacity Discovery research Pre-clinical Clinical trial
Ovarian cancer continuum
Cancer biology Prevention Early detection Treatment Survivorship
Targeting epitranscriptomic mechanisms in ovarian cancer
- Location
- Edmonton
- Lead scientist
- Dr. YangXin Fu
- Type of ovarian cancer
- All types
- Research continuum
- Pre-clinical
- Ovarian cancer continuum
- Treatment
Location
Edmonton
Lead scientist
Dr. YangXin Fu
Type of ovarian cancer
All types
Research continuum
Research capacity Discovery research Pre-clinical Clinical trial
Ovarian cancer continuum
Cancer biology Prevention Early detection Treatment Survivorship
CHARM Early Detection Clinical Trial
- Location
- Toronto
- Lead scientist
- Dr. Trevor Pugh
- Type of ovarian cancer
- High-grade serous Endometrioid Clear cell
- Research continuum
- Clinical trial
- Ovarian cancer continuum
- Early detection
Location
Toronto
Lead scientist
Dr. Trevor Pugh
Type of ovarian cancer
High-grade serous Endometrioid Clear cell
Research continuum
Research capacity Discovery research Pre-clinical Clinical trial
Ovarian cancer continuum
Cancer biology Prevention Early detection Treatment Survivorship
NEOCATS trial: Targeting the targets with a combination of three treatments
- Location
- Vancouver
- Lead scientist
- Dr. Yvette Drew
- Type of ovarian cancer
- High-grade serous
- Research continuum
- Clinical trial
- Ovarian cancer continuum
- Treatment
Location
Vancouver
Lead scientist
Dr. Yvette Drew
Type of ovarian cancer
High-grade serous
Research continuum
Research capacity Discovery research Pre-clinical Clinical trial
Ovarian cancer continuum
Cancer biology Prevention Early detection Treatment Survivorship
Developing new treatments for clear cell ovarian cancer
- Location
- Saskatoon
- Lead scientist
- Dr. Franco Vizeacoumar
- Type of ovarian cancer
- Clear cell
- Research continuum
- Pre-clinical
- Ovarian cancer continuum
- Treatment
Location
Saskatoon
Lead scientist
Dr. Franco Vizeacoumar
Type of ovarian cancer
Clear cell
Research continuum
Research capacity Discovery research Pre-clinical Clinical trial
Ovarian cancer continuum
Cancer biology Prevention Early detection Treatment Survivorship
Developing optimal treatment combinations for small cell carcinoma of the ovary
- Location
- Montreal
- Lead scientist
- Dr. Sidong Huang
- Type of ovarian cancer
- Non-epithelial
- Research continuum
- Pre-clinical
- Ovarian cancer continuum
- Treatment
Location
Montreal
Lead scientist
Dr. Sidong Huang
Type of ovarian cancer
Non-epithelial
Research continuum
Research capacity Discovery research Pre-clinical Clinical trial
Ovarian cancer continuum
Cancer biology Prevention Early detection Treatment Survivorship
Development of therapeutic vaccines against ovarian cancer
- Location
- Montreal
- Lead scientist
- Dr. Claude Perreault
- Type of ovarian cancer
- All types
- Research continuum
- Pre-clinical
- Ovarian cancer continuum
- Treatment
Location
Montreal
Lead scientist
Dr. Claude Perreault
Type of ovarian cancer
All types
Research continuum
Research capacity Discovery research Pre-clinical Clinical trial
Ovarian cancer continuum
Cancer biology Prevention Early detection Treatment Survivorship
Re-VOLVE trial: using genomics to make treatment decisions after a PARP inhibitor
- Location
- Toronto
- Lead scientist
- Dr. Stephanie Lheureux
- Type of ovarian cancer
- High-grade serous Endometrioid
- Research continuum
- Clinical trial
- Ovarian cancer continuum
- Treatment
Location
Toronto
Lead scientist
Dr. Stephanie Lheureux
Type of ovarian cancer
High-grade serous Endometrioid
Research continuum
Research capacity Discovery research Pre-clinical Clinical trial
Ovarian cancer continuum
Cancer biology Prevention Early detection Treatment Survivorship
A novel model system to study ovarian cancer/immune cell interactions
- Location
- Halifax
- Lead scientist
- Dr. Jeanette Boudreau
- Type of ovarian cancer
- All types
- Research continuum
- Research capacity
- Ovarian cancer continuum
- Cancer biology
Location
Halifax
Lead scientist
Dr. Jeanette Boudreau
Type of ovarian cancer
All types
Research continuum
Research capacity Discovery research Pre-clinical Clinical trial
Ovarian cancer continuum
Cancer biology Prevention Early detection Treatment Survivorship
Modelling low-grade serous cancer in 3D
- Location
- Vancouver
- Lead scientist
- Dr. Mark Carey
- Type of ovarian cancer
- Low-grade serous
- Research continuum
- Research capacity
- Ovarian cancer continuum
- Cancer biology
Location
Vancouver
Lead scientist
Dr. Mark Carey
Type of ovarian cancer
Low-grade serous
Research continuum
Research capacity Discovery research Pre-clinical Clinical trial
Ovarian cancer continuum
Cancer biology Prevention Early detection Treatment Survivorship